Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
April 16, 2024 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
April 09, 2024 16:30 ET
|
Foghorn Therapeutics, Inc.
First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2...
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
April 05, 2024 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
March 26, 2024 07:00 ET
|
Foghorn Therapeutics, Inc.
Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader...
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
March 07, 2024 07:00 ET
|
Foghorn Therapeutics, Inc.
• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024 • FHD-909, a first-in-class BRM selective inhibitor, selected for...
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909
March 05, 2024 16:48 ET
|
Foghorn Therapeutics, Inc.
Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024Oral...
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
February 28, 2024 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
February 08, 2024 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
January 08, 2024 07:00 ET
|
Foghorn Therapeutics, Inc.
- FHD-286 combination study in AML continues to progress in the clinic with data anticipated in the second half of 2024; preclinical combination data with FHD-286 and tyrosine kinase inhibitors (TKIs)...
Foghorn Therapeutics Announces CFO Departure
January 03, 2024 16:05 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...